DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Fradet Y, Bellmunt J, De Wit R. et al.
Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.
Journal of Clinical Oncol 2018;
36 (Suppl. 15) 4521-4521
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.